| Linking payment to health outcomes: a taxonomy and examination of performance-based reimbursement schemes between healthcare payers and manufacturers JJ Carlson, SD Sullivan, LP Garrison, PJ Neumann, DL Veenstra Health policy 96 (3), 179-190, 2010 | 364 | 2010 |
| Performance-based risk-sharing arrangements—good practices for design, implementation, and evaluation: report of the ISPOR good practices for performance-based risk-sharing … LP Garrison Jr, A Towse, A Briggs, G de Pouvourville, J Grueger, PE Mohr, ... Value in health 16 (5), 703-719, 2013 | 336 | 2013 |
| Donor availability as the primary determinant of the future of heart transplantation RW Evans, DL Manninen, LP Garrison, AM Maier Jama 255 (14), 1892-1898, 1986 | 259 | 1986 |
| Challenges in the development and reimbursement of personalized medicine—payer and manufacturer perspectives and implications for health economics and outcomes research: a … E Faulkner, L Annemans, L Garrison, M Helfand, AP Holtorf, J Hornberger, ... Value in Health 15 (8), 1162-1171, 2012 | 159 | 2012 |
| Pharmacoeconomic analysis of adjuvant oral capecitabine vs intravenous 5-FU/LV in Dukes' C colon cancer: the X-ACT trial J Cassidy, JY Douillard, C Twelves, JJ McKendrick, W Scheithauer, ... British journal of cancer 94 (8), 1122-1129, 2006 | 154 | 2006 |
| Pharmacoeconomic analysis of adjuvant oral capecitabine vs intravenous 5-FU/LV in Dukes' C colon cancer: the X-ACT trial J Cassidy, JY Douillard, C Twelves, JJ McKendrick, W Scheithauer, ... British journal of cancer 94 (8), 1122-1129, 2006 | 154 | 2006 |
| Can’t get no satisfaction? Will pay for performance help? Toward an economic framework for understanding performance-based risk-sharing agreements for innovative medical products A Towse, LP Garrison Pharmacoeconomics 28, 93-102, 2010 | 133 | 2010 |
| Good research practices for measuring drug costs in cost effectiveness analyses: issues and recommendations: the ISPOR Drug Cost Task Force Report—Part I JW Hay, J Smeeding, NV Carroll, M Drummond, LP Garrison, EC Mansley, ... Value in Health 13 (1), 3-7, 2010 | 125 | 2010 |
| Performance-based risk-sharing arrangements: an updated international review JJ Carlson, S Chen, LP Garrison Pharmacoeconomics 35, 1063-1072, 2017 | 106 | 2017 |
| Global eradication of measles: an epidemiologic and economic evaluation A Levin, C Burgess, LP Garrison, C Bauch, J Babigumira, E Simons, ... The Journal of infectious diseases 204 (suppl_1), S98-S106, 2011 | 105 | 2011 |
| Interspecialty variation in office-based care HP Greenwald, ML Peterson, LP Garrison, LG Hart, IS Moscovice, TL Hall, ... Medical care 22 (1), 14-29, 1984 | 103 | 1984 |
| A formal risk-benefit framework for genomic tests: facilitating the appropriate translation of genomics into clinical practice DL Veenstra, JA Roth, LP Garrison Jr, SD Ramsey, W Burke Genetics in Medicine 12 (11), 686-693, 2010 | 95 | 2010 |
| The potential clinical and economic outcomes of pharmacogenomic approaches to EGFR‐tyrosine kinase inhibitor therapy in non–small‐cell lung cancer JJ Carlson, LP Garrison, SD Ramsey, DL Veenstra Value in Health 12 (1), 20-27, 2009 | 91 | 2009 |
| Value-based pricing for emerging gene therapies: the economic case for a higher cost-effectiveness threshold LP Garrison, T Jackson, D Paul, M Kenston Journal of managed care & specialty pharmacy 25 (7), 793-799, 2019 | 89 | 2019 |
| Economic analysis of vaccination programs: an ISPOR good practices for outcomes research task force report J Mauskopf, B Standaert, MP Connolly, AJ Culyer, LP Garrison, ... Value in health 21 (10), 1133-1149, 2018 | 88 | 2018 |
| Value-based pricing and reimbursement in personalised healthcare: introduction to the basic health economics LP Garrison Jr, A Towse Journal of personalized medicine 7 (3), 10, 2017 | 84 | 2017 |
| Cost-effectiveness of bariatric surgical procedures for the treatment of severe obesity BCM Wang, ES Wong, R Alfonso-Cristancho, H He, DR Flum, ... The European Journal of Health Economics 15, 253-263, 2014 | 83 | 2014 |
| Interpretation of chronic pain clinical trial outcomes: IMMPACT recommended considerations SM Smith, RH Dworkin, DC Turk, MP McDermott, C Eccleston, JT Farrar, ... Pain 161 (11), 2446-2461, 2020 | 81 | 2020 |
| The use, safety and cost of bariatric surgery before and after Medicare's national coverage decision DR Flum, S Kwon, K MacLeod, B Wang, R Alfonso-Cristancho, ... Annals of surgery 254 (6), 860-865, 2011 | 81 | 2011 |
| Estimating the effect of changes in body mass index on health state preferences Z Hakim, A Wolf, LP Garrison Pharmacoeconomics 20, 393-404, 2002 | 80 | 2002 |
